Kabes J, Erban L, Hanzlicek L, Skondia V
J Int Med Res. 1979;7(4):277-84. doi: 10.1177/030006057900700404.
The purpose of this controlled clinical trial was to demonstrate possible correlations between changes in bioenergetic metabolism and psychotropic drug administration in the treatment of functional psychosis. The study included twenty-six patients, eleven with schizophrenia, three with chronic atypical depression and twelve with drug-resistant endogenous depressions. All patients were kept on continuous psychotropic medication for at least 3 weeks before starting the trial, and piracetam was given additionally in a fixed dosage of 2400 mg daily; the same number of identical capsules was given during the pre- and post-treatment placebo periods. Psycho-pathological evaluation of the patients was by the BPRS; clinical and biochemical data were evaluated statistically by the analysis of regression. The results show that in schizophrenic patients an improvement was observed in those cases who had improved biochemically, i.e. where the ATP values had increased. In drug-resistant depressions there was a rapid and significant clinical improvement after piracetam co-administration, and this went in step with a significant rise in ATP levels.
这项对照临床试验的目的是证明在功能性精神病治疗中生物能量代谢变化与精神药物给药之间可能存在的相关性。该研究纳入了26名患者，其中11名患有精神分裂症，3名患有慢性非典型抑郁症，12名患有耐药性内源性抑郁症。所有患者在开始试验前至少持续服用精神药物3周，并且额外给予固定剂量每日2400毫克的吡拉西坦；在治疗前和治疗后的安慰剂期给予相同数量的相同胶囊。通过简明精神病评定量表（BPRS）对患者进行精神病理学评估；通过回归分析对临床和生化数据进行统计学评估。结果显示，在精神分裂症患者中，生化指标改善（即ATP值升高）的患者病情有所改善。在耐药性抑郁症患者中，联合使用吡拉西坦后临床症状迅速且显著改善，这与ATP水平的显著升高同步。
